- Home
- AEON vs KPRX Comparison
AEON vs KPRX Comparison
Compare AEON & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEON
- KPRX
- Stock Information
- Founded
- AEON N/A
- KPRX 1998
- Country
- AEON United States
- KPRX United States
- Employees
- AEON N/A
- KPRX N/A
- Industry
- AEON Biotechnology: Pharmaceutical Preparations
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- AEON Health Care
- KPRX Health Care
- Exchange
- AEON Nasdaq
- KPRX Nasdaq
- Market Cap
- AEON 8.0M
- KPRX 9.1M
- IPO Year
- AEON N/A
- KPRX N/A
- Fundamental
- Price
- AEON $0.75
- KPRX $2.90
- Analyst Decision
- AEON Strong Buy
- KPRX Strong Buy
- Analyst Count
- AEON 1
- KPRX 1
- Target Price
- AEON $360.00
- KPRX $10.00
- AVG Volume (30 Days)
- AEON 435.1K
- KPRX 1.3M
- Earning Date
- AEON 08-11-2025
- KPRX 08-08-2025
- Dividend Yield
- AEON N/A
- KPRX N/A
- EPS Growth
- AEON N/A
- KPRX N/A
- EPS
- AEON 117.22
- KPRX N/A
- Revenue
- AEON N/A
- KPRX $20,000.00
- Revenue This Year
- AEON N/A
- KPRX N/A
- Revenue Next Year
- AEON N/A
- KPRX N/A
- P/E Ratio
- AEON $0.01
- KPRX N/A
- Revenue Growth
- AEON N/A
- KPRX N/A
- 52 Week Low
- AEON $0.38
- KPRX $2.51
- 52 Week High
- AEON $269.28
- KPRX $4.86
- Technical
- Relative Strength Index (RSI)
- AEON 50.96
- KPRX 43.33
- Support Level
- AEON $0.68
- KPRX $2.87
- Resistance Level
- AEON $0.81
- KPRX $3.22
- Average True Range (ATR)
- AEON 0.09
- KPRX 0.18
- MACD
- AEON -0.01
- KPRX -0.02
- Stochastic Oscillator
- AEON 18.64
- KPRX 5.77
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.